Researchers develop first synthetic inhibitor of coagulation factor XII
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
List view / Grid view
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
A group of researchers has suggested that BBOX1 inhibitors could be used to treat triple negative breast cancer after showing success in mouse models.
A new study has shown that while chloroquine protects African green monkey kidney cells from SARS-CoV-2 infection, it does not protect human lung cells.
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
The novel aryl hydrocarbon receptor (AHR) inhibiting drug slowed zika virus replication and prevented mouse foetuses malforming in infected mothers.
The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.